Abstract
Background
Precision medicine approaches for managing patients with metastatic castrate-resistant prostate cancer (mCRPC) are lacking. Non-invasive approaches for molecular monitoring of disease are urgently needed, especially for patients suffering from bone metastases for whom tissue biopsy is challenging. Here we utilized baseline blood samples to identify mCRPC patients most likely to benefit from abiraterone plus prednisone (AAP) or enzalutamide.
Methods
Baseline blood samples were collected for circulating tumor cell (CTC) enumeration and qPCR-based gene expression analysis from 51 men with mCRPC beginning treatment with abiraterone or enzalutamide.
Results
Of 51 patients (median age 68 years [51–82]), 22 received AAP (abiraterone 1000 mg/day plus prednisone 10 mg/day) and 29 received enzalutamide (160 mg/day). The cohort was randomly divided into training (n = 37) and test (n = 14) sets. Baseline clinical variables (Gleason score, PSA, testosterone, and hemoglobin), CTC count, and qPCR-based gene expression data for 141 genes/isoforms in CTC-enriched blood were analyzed with respect to overall survival (OS). Genes with expression most associated with OS included MSLN, ARG2, FGF8, KLK3, ESRP2, NPR3, CCND1, and WNT5A. Using a Cox-elastic net model for our test set, the 8-gene expression signature had a c-index of 0.87 (95% CI [0.80, 0.94]) and was more strongly associated with OS than clinical variables or CTC count alone, or a combination of the three variables. For patients with a low-risk vs. high-risk gene expression signature, median OS was not reached vs. 18 months, respectively (HR 5.32 [1.91–14.80], p = 0.001). For the subset of 41 patients for whom progression-free survival (PFS) data was available, the median PFS for patients with a low-risk vs high-risk gene expression signature was 20 vs. 5 months, respectively (HR 2.95 [1.46–5.98], p = 0.003).
Conclusions
If validated in a larger prospective study, this test may predict patients most likely to benefit from second-generation antiandrogen therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
American Cancer Society. Cancer Facts & Figures 2020. American Cancer Society: Atlanta, 2020.
Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–433.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995–2005.
Han GC, Hwang J, Wankowicz SA, Zhang Z, Liu D, Cibulskis C, et al. Genomic resistance patterns to second-generation androgen blockade in paired tumor biopsies of metastatic castration-resistant prostate cancer. JCO Precis Oncol. 2017;1:1–11.
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, et al. Circulating tumor cell number as a response measure of prolonged survival for metastatic castration-resistant prostate cancer: a comparison with prostate-specific antigen across five randomized phase III clinical trials. J Clin Oncol. 2018;36:572–580.
Danila DC, Anand A, Schultz N, Heller G, Wan M, Sung CC, et al. Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. Eur Urol. 2014;65:1191–1197.
Scher HI, Lu D, Schreiber NA, Louw J, Graf RP, Vargas HA, et al. Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate cancer. JAMA Oncol. 2016;2:1441–1449.
Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028–1038.
Azad AA, Volik SV, Wyatt AW, Haegert A, Le Bihan S, Bell RH, et al. Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer. Clin Cancer Res. 2015;21:2315–2324.
Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA. 2019;116:11428–11436.
Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361–387.
Halabi S, Lin CY, Kelly WK, Fizazi KS, Moul JW, Kaplan EB, et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol. 2014;32:671–677.
De Laere B, Oeyen S, Van Oyen P, Ghysel C, Ampe J, Ost P, et al. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer. Prostate. 2018;78:435–445.
Leon-Mateos L, Casas H, Abalo A, Vieito M, Abreu M, Anido U, et al. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients. Oncotarget. 2017;8:54708–54721.
Huang CG, Li FX, Pan S, Xu CB, Dai JQ, Zhao XH. Identification of genes associated with castrationresistant prostate cancer by gene expression profile analysis. Mol Med Rep. 2017;16:6803–6813.
Ashida S, Nakagawa H, Katagiri T, Furihata M, Iiizumi M, Anazawa Y, et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004;64:5963–5972.
Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.
Thul PJ, Åkesson L, Wiking M, Mahdessian D, Geladaki A, Blal HA, et al. A subcellular map of the human proteome. Science. 2017;356:eaal3321.
Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357:eaan2507.
Human Protein Atlas. http://www.proteinatlas.org.
NPR3 Pathology. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000113389-NPR3/pathology.
ESRP2 Pathology. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000103067-ESRP2/pathology.
Munkley J, Li L, Krishnan SRG, Hysenaj G, Scott E, Dalgliesh C, et al. Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer. Elife. 2019;8:e47678.
Yang Y, Park JW, Bebee TW, Warzecha CC, Guo Y, Shang X, et al. Determination of a comprehensive alternative splicing regulatory network and combinatorial regulation by key factors during the epithelial-to-mesenchymal transition. Mol Cell Biol. 2016;36:1704–1719.
Dorkin TJ, Robinson MC, Marsh C, Bjartell A, Neal DE, Leung HY. FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease. Oncogene. 1999;18:2755–2761.
Gnanapragasam VJ, Robinson MC, Marsh C, Robson CN, Hamdy FC, Leung HY. FGF8 isoform b expression in human prostate cancer. Br J Cancer. 2003;88:1432–1438.
Corn PG, Wang F, McKeehan WL, Navone N. Targeting fibroblast growth factor pathways in prostate cancer. Clin Cancer Res. 2013;19:5856–5866.
Maruyama‐Takahashi K, Shimada N, Imada T, Maekawa‐Tokuda Y, Ishii T, Ouchi J, et al. A neutralizing anti‐fibroblast growth factor (FGF) 8 monoclonal antibody shows anti‐tumor activity against FGF8b‐expressing LNCaP xenografts in androgen‐dependent and‐independent conditions. Prostate. 2008;68:640–650.
ARG2 Pathology. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000081181-ARG2/pathology.
Mumenthaler SM, Yu H, Tze S, Cederbaum SD, Pegg AE, Seligson DB, et al. Expression of arginase II in prostate cancer. Int J Oncol. 2008;32:357–365.
ARG2 Tissue. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000081181-ARG2/tissue.
Gannon PO, Godin-Ethier J, Hassler M, Delvoye N, Aversa M, Poisson AO, et al. Androgen-regulated expression of arginase 1, arginase 2 and interleukin-8 in human prostate cancer. PLoS One. 2010;5:e12107.
Ren D, Dai Y, Yang Q, Zhang X, Guo W, Ye L, et al. Wnt5a induces and maintains prostate cancer cells dormancy in bone. J Exp Med. 2019;216:428–449.
Lee GT, Kwon SJ, Kim J, Kwon YS, Lee N, Hong JH, et al. WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages. Br J Cancer. 2018;118:670–678.
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ, Zhu H, Broderick KT, et al. RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. Science. 2015;349:1351–1356.
Inaguma S, Wang Z, Lasota J, Onda M, Czapiewski P, Langfort R, et al. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma. Oncotarget. 2017;8:26744–26754.
MSLN Pathology. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000102854-MSLN/pathology.
MSLN Blood. Human Protein Atlas. https://www.proteinatlas.org/ENSG00000102854-MSLN/blood.
Acknowledgements
NBH and MJL contributed equally to this work. NBH, DS, KEW, and ELC conceptualized this study, and MJL, NBH, YC, KCN, BF, JP, DS, THB, KJM, SSY, TAB, SG, SLS, EJM, QL, and ELC acquired, analyzed, and interpreted the data. MJL, YC, THB, and ELC drafted this manuscript, and NBH, KCN, DS, SKP, JOJ, MH, and SSY revised it critically. NBH, DJV, and RA provided care for enrolled patients as well as clinical input on patient characteristics. MJL, NBH, YC, KCN, DS, THB, SSY, and ELC prepared the manuscript for publication and agree to be accountable for the accuracy and integrity of all aspects of this study. The authors thank the Abramson Cancer Center for support from the Cancer Center Support Grant P30CA016520.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
YC, KCN, SG, BF, JP, and DS are or were employed by Janssen. QL receives research funding from Bayer and Pfizer. ELC, NBH, and JJ receive funding from Janssen. ELC receives research funding from Merck. The authors thank the Abramson Cancer Center for support from the Cancer Center Support Grant P30CA016520.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Haas, N.B., LaRiviere, M.J., Buckingham, T.H. et al. Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. Prostate Cancer Prostatic Dis 24, 448–456 (2021). https://doi.org/10.1038/s41391-020-00295-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41391-020-00295-z